$ABL
Abacus Life, Inc.

2024 Q3 Form 10-Q Financial Statement

#000181428724000051 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $28.15M $29.08M
YoY Change 33.27% 155.53%
Cost Of Revenue $2.188M $2.744M
YoY Change -34.98% 181.85%
Gross Profit $25.96M $26.33M
YoY Change 46.21% 153.07%
Gross Profit Margin 92.23% 90.56%
Selling, General & Admin $17.66M $17.11M
YoY Change 52.98% 1256.15%
% of Gross Profit 68.02% 64.96%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.745M $1.750M
YoY Change 2.98% 159321.86%
% of Gross Profit 6.72% 6.65%
Operating Expenses $19.11M $19.56M
YoY Change 66.82% 861.38%
Operating Profit $6.850M $6.771M
YoY Change 8.73% -19.11%
Interest Expense -$3.191M -$3.395M
YoY Change -219.11% -681.26%
% of Operating Profit -46.59% -50.14%
Other Income/Expense, Net -$12.39M -$4.361M
YoY Change 249.99% 843.04%
Pretax Income -$5.535M $2.409M
YoY Change -300.55% -69.54%
Income Tax -$250.4K $1.758M
% Of Pretax Income 72.95%
Net Earnings -$5.125M $770.0K
YoY Change -667.33% -88.59%
Net Earnings / Revenue -18.21% 2.65%
Basic Earnings Per Share -$0.07 $0.01
Diluted Earnings Per Share -$0.07 $0.01
COMMON SHARES
Basic Shares Outstanding 74.65M shares 63.93M shares
Diluted Shares Outstanding 74.69M shares 67.16M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.43M $95.33M
YoY Change -38.72% 362.78%
Cash & Equivalents $19.41M $91.32M
Short-Term Investments $3.019M $4.008M
Other Short-Term Assets $2.071M $932.6K
YoY Change 107.09% 16.58%
Inventory
Prepaid Expenses
Receivables $3.595M $2.937M
Other Receivables $2.702M $2.435M
Total Short-Term Assets $30.80M $101.6M
YoY Change -22.07% 215.58%
LONG-TERM ASSETS
Property, Plant & Equipment $888.5K $692.3K
YoY Change 239.28% 289.07%
Goodwill $139.9M $139.9M
YoY Change -0.25% -0.25%
Intangibles $24.65M $26.35M
YoY Change -21.03% -19.9%
Long-Term Investments $277.4M $211.6M
YoY Change 202.13% 205.82%
Other Assets $1.651M $1.507M
YoY Change 65.07% -16.34%
Total Long-Term Assets $446.5M $382.2M
YoY Change 68.63% 55.93%
TOTAL ASSETS
Total Short-Term Assets $30.80M $101.6M
Total Long-Term Assets $446.5M $382.2M
Total Assets $477.3M $483.9M
YoY Change 56.85% 74.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $2.535M $2.177M
YoY Change 298.14% 315.05%
Deferred Revenue $924.1K $1.443M
YoY Change 164.9% 47.11%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $13.73M $45.76M
YoY Change
Total Short-Term Liabilities $23.86M $55.38M
YoY Change 337.23% 298.6%
LONG-TERM LIABILITIES
Long-Term Debt $166.5M $151.3M
YoY Change 40.16% 65.91%
Other Long-Term Liabilities $16.99M $8.310M
YoY Change 399.73% 232.39%
Total Long-Term Liabilities $183.5M $159.6M
YoY Change 50.17% 70.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.86M $55.38M
Total Long-Term Liabilities $183.5M $159.6M
Total Liabilities $219.4M $227.0M
YoY Change 58.72% 94.29%
SHAREHOLDERS EQUITY
Retained Earnings -$39.64M -$34.51M
YoY Change 39.07% 17.47%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $258.0M $256.8M
YoY Change
Total Liabilities & Shareholders Equity $477.3M $483.9M
YoY Change 56.85% 74.47%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$5.125M $770.0K
YoY Change -667.33% -88.59%
Depreciation, Depletion And Amortization $1.745M $1.750M
YoY Change 2.98% 159321.86%
Cash From Operating Activities -$52.28M -$66.81M
YoY Change 307.84% 218.44%
INVESTING ACTIVITIES
Capital Expenditures $242.6K $199.3K
YoY Change 142.55%
Acquisitions
YoY Change
Other Investing Activities -$208.5K -$510.2K
YoY Change -102.14% -91.58%
Cash From Investing Activities -$451.1K -$709.5K
YoY Change -104.68% -88.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -19.18M 93.46M
YoY Change -199.78% 234.61%
NET CHANGE
Cash From Operating Activities -52.28M -66.81M
Cash From Investing Activities -451.1K -709.5K
Cash From Financing Activities -19.18M 93.46M
Net Change In Cash -71.91M 25.94M
YoY Change -548.62% 2814.31%
FREE CASH FLOW
Cash From Operating Activities -$52.28M -$66.81M
Capital Expenditures $242.6K $199.3K
Free Cash Flow -$52.53M -$67.01M
YoY Change 306.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-1275471 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-112313 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
7624796 usd
us-gaap Revenues
Revenues
50563286 usd
us-gaap Gross Profit
GrossProfit
45098855 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2176515 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4354225 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297397 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
118058 usd
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1443483 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
507000 usd
CY2024Q2 abl Accrued Transaction Costs Current
AccruedTransactionCostsCurrent
2533627 usd
CY2023Q4 abl Accrued Transaction Costs Current
AccruedTransactionCostsCurrent
0 usd
CY2024Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0 usd
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
751734 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
55383057 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23326331 usd
CY2024Q2 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
81640478 usd
CY2023Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
55318923 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1946140 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1796727 usd
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12001423 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
9199091 usd
CY2024Q2 abl Warrant Liabilities Noncurrent
WarrantLiabilitiesNoncurrent
6363500 usd
CY2023Q4 abl Warrant Liabilities Noncurrent
WarrantLiabilitiesNoncurrent
6642960 usd
CY2024Q2 us-gaap Liabilities
Liabilities
227005417 usd
CY2023Q4 us-gaap Liabilities
Liabilities
167755991 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1048226 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
146650 shares
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
12025137 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1283062 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
303237878 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
199826278 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34514318 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34726135 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
64324 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
108373 usd
CY2024Q2 us-gaap Minority Interest
MinorityInterest
79193 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
138283 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
256849488 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
164070076 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
483854905 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
331826067 usd
us-gaap Insurance Services Revenue
InsuranceServicesRevenue
46810756 usd
us-gaap Insurance Services Revenue
InsuranceServicesRevenue
20994917 usd
us-gaap Revenues
Revenues
21584974 usd
us-gaap Cost Of Revenue
CostOfRevenue
5464431 usd
us-gaap Cost Of Revenue
CostOfRevenue
1462950 usd
us-gaap Gross Profit
GrossProfit
20122024 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4482745 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1412845 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25906843 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1274431 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-3912090 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-2398662 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
802484 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
798156 usd
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
856744 usd
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
0 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3432506 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2141 usd
us-gaap Operating Expenses
OperatingExpenses
36074956 usd
us-gaap Operating Expenses
OperatingExpenses
4289923 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
9023899 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
15832101 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-279460 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
8199632 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
941458 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1061332 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
7457 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
142442 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21651 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6716398 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-955652 usd
us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
2307501 usd
us-gaap Income Loss Including Portion Attributable To Noncontrolling Interest
IncomeLossIncludingPortionAttributableToNoncontrollingInterest
14876449 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2931223 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
528104 usd
us-gaap Profit Loss
ProfitLoss
-623722 usd
us-gaap Profit Loss
ProfitLoss
14348345 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-44960 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-487303 usd
us-gaap Net Income Loss
NetIncomeLoss
-578762 usd
us-gaap Net Income Loss
NetIncomeLoss
14835648 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.29
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63846170 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50507728 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63087878 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50438921 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67162820 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50507728 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63102210 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50438921 shares
CY2024Q2 us-gaap Profit Loss
ProfitLoss
651749 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
6723549 usd
us-gaap Profit Loss
ProfitLoss
-623722 usd
us-gaap Profit Loss
ProfitLoss
14348345 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
-65615 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
-119663 usd
us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
-58179 usd
us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
-231976 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-681901 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
14116369 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-59090 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-543749 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-622811 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
14660118 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
164070076 usd
CY2024Q1 abl Stockholders Equity Deferred Transaction Costs
StockholdersEquityDeferredTransactionCosts
483451 usd
CY2024Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
7524392 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6093371 usd
CY2024Q1 abl Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
4453203 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7436 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
165340772 usd
CY2024Q2 abl Stockholders Equity Deferred Transaction Costs
StockholdersEquityDeferredTransactionCosts
-790579 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
92000000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
7213627 usd
CY2024Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
3217683 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6165459 usd
CY2024Q2 abl Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2397854 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-65615 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
651749 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
256849488 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
28149697 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
35662180 usd
CY2023Q2 us-gaap Dividends
Dividends
34451607 usd
CY2023Q2 abl Stockholders Equity Deferred Transaction Costs
StockholdersEquityDeferredTransactionCosts
10841551 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
960900 usd
CY2023Q2 abl Stock Issued During Period Value Reverse Recapitalization
StockIssuedDuringPeriodValueReverseRecapitalization
-2796225 usd
CY2023Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
165361332 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-119663 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
6723549 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
160498915 usd
us-gaap Profit Loss
ProfitLoss
-623722 usd
us-gaap Profit Loss
ProfitLoss
14348345 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3432506 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2141 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12258830 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
451234 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
802484 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
798156 usd
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
856744 usd
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
0 usd
us-gaap Life Settlement Contracts Fair Value Method Unrealized Gain Loss
LifeSettlementContractsFairValueMethodUnrealizedGainLoss
21341703 usd
us-gaap Life Settlement Contracts Fair Value Method Unrealized Gain Loss
LifeSettlementContractsFairValueMethodUnrealizedGainLoss
3319588 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-3912090 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-2398662 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-279460 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
us-gaap Interest Income Operating Paid In Kind
InterestIncomeOperatingPaidInKind
59640 usd
us-gaap Interest Income Operating Paid In Kind
InterestIncomeOperatingPaidInKind
0 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
3969473 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
252659 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
2551404 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
0 usd
abl Operating Lease Right Of Use Asset Noncash Income Expense
OperatingLeaseRightOfUseAssetNoncashIncomeExpense
-114377 usd
abl Operating Lease Right Of Use Asset Noncash Income Expense
OperatingLeaseRightOfUseAssetNoncashIncomeExpense
-384 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-532435 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
182147 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
70704 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-125764 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
233471 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
193462 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
508486 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
105655 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
361486 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2177710 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 usd
abl Increase Decrease In Accrued Transaction Costs
IncreaseDecreaseInAccruedTransactionCosts
2533627 usd
abl Increase Decrease In Accrued Transaction Costs
IncreaseDecreaseInAccruedTransactionCosts
-725685 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
936483 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-1717402 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
402363 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-751734 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
2435239 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
0 usd
abl Life Settlement Contract Purchased Fair Value Method
LifeSettlementContractPurchasedFairValueMethod
63933151 usd
abl Life Settlement Contract Purchased Fair Value Method
LifeSettlementContractPurchasedFairValueMethod
39556677 usd
abl Life Settlement Contract Purchased Investment Method
LifeSettlementContractPurchasedInvestmentMethod
-556681 usd
abl Life Settlement Contract Purchased Investment Method
LifeSettlementContractPurchasedInvestmentMethod
11374605 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-64542510 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38364171 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
350917 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
102135 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
100000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
300000 usd
abl Proceeds Due From Payments Due To Affiliates
ProceedsDueFromPaymentsDueToAffiliates
-163061 usd
abl Proceeds Due From Payments Due To Affiliates
ProceedsDueFromPaymentsDueToAffiliates
-6760627 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-716113 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7060627 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1688926 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
92000000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5730000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
10742075 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
483451 usd
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
10841551 usd
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
1159712 usd
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
23533072 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6851057 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
0 usd
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
10151369 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
130993784 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35983097 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
65735161 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9441701 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25588668 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30052823 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91323829 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20611122 usd
us-gaap Interest Paid Net
InterestPaidNet
4635611 usd
us-gaap Interest Paid Net
InterestPaidNet
773282 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2691871 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14pt">BASIS OF PRESENTATION</span><div style="margin-top:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements (“Interim Financial Statements”) are presented in accordance with the rules and regulations of the United States ("U.S.") Securities and Exchange Commission ("SEC") and do not include all of the disclosures normally required by U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) as contained in the Company’s Annual Report on Form 10-K. We have condensed or omitted certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP. Accordingly, the consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 21, 2024, as amended by Amendment No. 1 on Form 10-K/A, filed with the SEC on May 30, 2024, and as amended by Amendment No. 2 on Form 10-K/A, filed with the SEC on June 12, 2024 (“2023 Annual Report”). Refer to Note 2 in the Company’s 2023 Annual Report for the full list of the Company’s significant accounting policies. The details in those notes have not changed, except as discussed in Note 2 to the Interim Financial Statements and as a result of normal adjustments in the interim periods. Capitalized terms used and not specifically defined herein have the same meanings given those terms in our 2023 Annual Report. We also may use certain other terms that are defined within these Interim Financial Statements.</span></div><div style="margin-top:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Interim Financial Statements presented herein and discussed below include 100% of the assets, liabilities, revenues, expenses, and cash flows of Abacus Life, Inc., (the “Company”) all entities in which the Company has a controlling voting interest (“subsidiaries”), and variable interest entities (“VIEs”) for which the Company is the primary beneficiary, as determined in accordance with consolidation accounting guidance. References in these Interim Financial Statements to net income or loss attributable to common stockholders and stockholders’ equity do not include noncontrolling interests, which represent the outside ownership of our consolidated non-wholly owned entity and are reported separately. Intercompany accounts and transactions between consolidated entities have been eliminated in consolidation.</span></div><div style="margin-top:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Interim Financial Statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2024, and the consolidated statements of operations and comprehensive (loss) income for the three and six months ended June 30, 2024 and 2023, respectively, and the consolidated statements of cash flows for the six months ended June 30, 2024 and 2023, respectively. The Interim Financial Statements are not necessarily indicative of the results to be expected for the full year, or any other period. All references to financial information in the Interim Financial Statements in the condensed notes to Interim Financial Statements are unaudited.</span></div><div style="margin-top:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, revenue recognition, cost of revenue, life settlement policy valuation, goodwill and intangibles valuation, market-indexed note valuation, and income taxes. The uncertainties in the broader macroeconomic environment have made it more challenging to make these estimates. Actual results could differ from our estimates, and such differences may be material.</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Certain prior period amounts have been reclassified to conform to current presentation.</span></div>
CY2024Q2 us-gaap Insurance Investment Income
InsuranceInvestmentIncome
7393 usd
CY2023Q2 us-gaap Insurance Investment Income
InsuranceInvestmentIncome
8263499 usd
us-gaap Insurance Investment Income
InsuranceInvestmentIncome
507393 usd
us-gaap Insurance Investment Income
InsuranceInvestmentIncome
16655833 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Gain Loss
LifeSettlementContractsFairValueMethodGainLoss
27006364 usd
CY2023Q2 us-gaap Life Settlement Contracts Fair Value Method Gain Loss
LifeSettlementContractsFairValueMethodGainLoss
2760900 usd
us-gaap Life Settlement Contracts Fair Value Method Gain Loss
LifeSettlementContractsFairValueMethodGainLoss
46303363 usd
us-gaap Life Settlement Contracts Fair Value Method Gain Loss
LifeSettlementContractsFairValueMethodGainLoss
4339084 usd
CY2024Q2 us-gaap Insurance Services Revenue
InsuranceServicesRevenue
27013757 usd
CY2023Q2 us-gaap Insurance Services Revenue
InsuranceServicesRevenue
11024399 usd
us-gaap Insurance Services Revenue
InsuranceServicesRevenue
46810756 usd
us-gaap Insurance Services Revenue
InsuranceServicesRevenue
20994917 usd
CY2024Q2 us-gaap Revenues
Revenues
29076102 usd
CY2023Q2 us-gaap Revenues
Revenues
11378765 usd
us-gaap Revenues
Revenues
50563286 usd
us-gaap Revenues
Revenues
21584974 usd
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1443483 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
507000 usd
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1443483 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
507000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
507000 usd
CY2024Q2 abl Life Settlement Contracts Number Of Contracts
LifeSettlementContractsNumberOfContracts
458 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Number Of Contracts
LifeSettlementContractsFairValueMethodNumberOfContracts
452 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Number Of Contracts
LifeSettlementContractsInvestmentMethodNumberOfContracts
6 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Face Value
LifeSettlementContractsFairValueMethodFaceValue
744204632 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Carrying Amount
LifeSettlementContractsFairValueMethodCarryingAmount
207571413 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Face Value
LifeSettlementContractsInvestmentMethodFaceValue
3725000 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Carrying Amount
LifeSettlementContractsInvestmentMethodCarryingAmount
1140497 usd
CY2023Q4 abl Life Settlement Contracts Number Of Contracts
LifeSettlementContractsNumberOfContracts
296 insurance_contract
CY2023Q4 us-gaap Life Settlement Contracts Fair Value Method Number Of Contracts
LifeSettlementContractsFairValueMethodNumberOfContracts
287 insurance_contract
CY2023Q4 us-gaap Life Settlement Contracts Investment Method Number Of Contracts
LifeSettlementContractsInvestmentMethodNumberOfContracts
9 insurance_contract
CY2023Q4 us-gaap Life Settlement Contracts Fair Value Method Face Value
LifeSettlementContractsFairValueMethodFaceValue
520503710 usd
CY2023Q4 us-gaap Life Settlement Contracts Fair Value Method Carrying Amount
LifeSettlementContractsFairValueMethodCarryingAmount
122296559 usd
CY2023Q4 us-gaap Life Settlement Contracts Investment Method Face Value
LifeSettlementContractsInvestmentMethodFaceValue
33900000 usd
CY2023Q4 us-gaap Life Settlement Contracts Investment Method Carrying Amount
LifeSettlementContractsInvestmentMethodCarryingAmount
1697178 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Remainder Of Fiscal Year
LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInRemainderOfFiscalYear
5 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Face Value Maturing In Remainder Of Fiscal Year
LifeSettlementContractsFairValueMethodFaceValueMaturingInRemainderOfFiscalYear
10300000 usd
CY2024Q2 abl Life Settlement Contract Fair Value Method Net Death Benefit Maturity Remainder Of Fiscal Year
LifeSettlementContractFairValueMethodNetDeathBenefitMaturityRemainderOfFiscalYear
10300000 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Maturing In Remainder Of Fiscal Year
LifeSettlementContractsFairValueMaturingInRemainderOfFiscalYear
8613599 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Next Twelve Months
LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInNextTwelveMonths
21 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Face Value Maturing In Next Twelve Months
LifeSettlementContractsFairValueMethodFaceValueMaturingInNextTwelveMonths
10699565 usd
CY2024Q2 abl Life Settlement Contract Fair Value Method Net Death Benefit Maturity Year One
LifeSettlementContractFairValueMethodNetDeathBenefitMaturityYearOne
13956836 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Maturing In Next Twelve Months
LifeSettlementContractsFairValueMaturingInNextTwelveMonths
9144801 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Two
LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearTwo
53 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Face Value Maturing In Year Two
LifeSettlementContractsFairValueMethodFaceValueMaturingInYearTwo
111626442 usd
CY2024Q2 abl Life Settlement Contract Fair Value Method Net Death Benefit Maturity Year Two
LifeSettlementContractFairValueMethodNetDeathBenefitMaturityYearTwo
108026835 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Maturing In Year Two
LifeSettlementContractsFairValueMaturingInYearTwo
54014913 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Three
LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearThree
59 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Face Value Maturing In Year Three
LifeSettlementContractsFairValueMethodFaceValueMaturingInYearThree
108955620 usd
CY2024Q2 abl Life Settlement Contract Fair Value Method Net Death Benefit Maturity Year Three
LifeSettlementContractFairValueMethodNetDeathBenefitMaturityYearThree
110369108 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Maturing In Year Three
LifeSettlementContractsFairValueMaturingInYearThree
46779787 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Four
LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearFour
46 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Face Value Maturing In Year Four
LifeSettlementContractsFairValueMethodFaceValueMaturingInYearFour
69995254 usd
CY2024Q2 abl Life Settlement Contract Fair Value Method Net Death Benefit Maturity Year Four
LifeSettlementContractFairValueMethodNetDeathBenefitMaturityYearFour
68382407 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Maturing In Year Four
LifeSettlementContractsFairValueMaturingInYearFour
22873318 usd
CY2024Q2 abl Life Settlement Contract Fair Value Method Number Of Contracts Maturity After Year Four
LifeSettlementContractFairValueMethodNumberOfContractsMaturityAfterYearFour
268 insurance_contract
CY2024Q2 abl Life Settlement Contract Fair Value Method Face Value Maturity After Year Four
LifeSettlementContractFairValueMethodFaceValueMaturityAfterYearFour
432627751 usd
CY2024Q2 abl Life Settlement Contract Fair Value Method Net Death Benefit Maturity After Year Four
LifeSettlementContractFairValueMethodNetDeathBenefitMaturityAfterYearFour
433817206 usd
CY2024Q2 abl Life Settlement Contract Fair Value Maturity After Year Four
LifeSettlementContractFairValueMaturityAfterYearFour
66144995 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Number Of Contracts
LifeSettlementContractsFairValueMethodNumberOfContracts
452 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Face Value
LifeSettlementContractsFairValueMethodFaceValue
744204632 usd
CY2024Q2 abl Life Settlement Contracts Fair Value Method Net Death Benefit
LifeSettlementContractsFairValueMethodNetDeathBenefit
744852392 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Carrying Amount
LifeSettlementContractsFairValueMethodCarryingAmount
207571413 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Number Of Contracts Maturing In Next Twelve Months
LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths
1 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Face Value Maturing In Next Twelve Months
LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths
625000 usd
CY2024Q2 abl Life Settlement Contract Investment Method Net Death Benefit Maturity Year One
LifeSettlementContractInvestmentMethodNetDeathBenefitMaturityYearOne
650059 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Carrying Amount Maturing In Next Twelve Months
LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInNextTwelveMonths
329714 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Two
LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo
2 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Face Value Maturing In Year Two
LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo
2250000 usd
CY2024Q2 abl Life Settlement Contract Investment Method Net Death Benefit Maturity Year Two
LifeSettlementContractInvestmentMethodNetDeathBenefitMaturityYearTwo
2250000 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Two
LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearTwo
468095 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Four
LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour
2 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Face Value Maturing In Year Four
LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFour
750000 usd
CY2024Q2 abl Life Settlement Contract Investment Method Net Death Benefit Maturity Year Four
LifeSettlementContractInvestmentMethodNetDeathBenefitMaturityYearFour
750000 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Four
LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearFour
327942 usd
CY2024Q2 abl Life Settlement Contract Investment Method Number Of Contracts Maturity After Year Four
LifeSettlementContractInvestmentMethodNumberOfContractsMaturityAfterYearFour
1 insurance_contract
CY2024Q2 abl Life Settlement Contract Investment Method Face Value Maturity After Year Four
LifeSettlementContractInvestmentMethodFaceValueMaturityAfterYearFour
100000 usd
CY2024Q2 abl Life Settlement Contract Investment Method Net Death Benefit Maturity After Year Four
LifeSettlementContractInvestmentMethodNetDeathBenefitMaturityAfterYearFour
100331 usd
CY2024Q2 abl Life Settlement Contract Investment Method Amount Maturity After Year Four
LifeSettlementContractInvestmentMethodAmountMaturityAfterYearFour
14746 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Number Of Contracts
LifeSettlementContractsInvestmentMethodNumberOfContracts
6 insurance_contract
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Face Value
LifeSettlementContractsInvestmentMethodFaceValue
3725000 usd
CY2024Q2 abl Life Settlement Contracts Investment Method Net Death Benefit
LifeSettlementContractsInvestmentMethodNetDeathBenefit
3750390 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Carrying Amount
LifeSettlementContractsInvestmentMethodCarryingAmount
1140497 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Premiums To Be Paid In Remainder Of Fiscal Year
LifeSettlementContractsInvestmentMethodPremiumsToBePaidInRemainderOfFiscalYear
36001 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Premiums To Be Paid In Next Twelve Months
LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths
93058 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Premiums To Be Paid In Year Two
LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo
67821 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Premiums To Be Paid In Year Three
LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree
42421 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Premiums To Be Paid In Year Four
LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFour
22185 usd
CY2024Q2 abl Life Settlement Contract Investment Method Premium To Be Paid After Year Four
LifeSettlementContractInvestmentMethodPremiumToBePaidAfterYearFour
154286 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Five Year Disclosure Premiums To Be Paid
LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid
415772 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
821398 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
470482 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
129125 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
69762 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
692273 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
400720 usd
CY2024Q2 us-gaap Depreciation
Depreciation
44418 usd
CY2023Q2 us-gaap Depreciation
Depreciation
1098 usd
us-gaap Depreciation
Depreciation
59363 usd
us-gaap Depreciation
Depreciation
2141 usd
CY2024Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
32900000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
29300000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6728333 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22571667 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1682083 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3364167 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
3364167 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
5328333 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3911667 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3895000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2635000 usd
CY2024Q2 abl Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
3437500 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22571667 usd
CY2024Q2 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
180456 usd
CY2023Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
87297 usd
CY2024Q2 abl Debt Securities Available For Sale Principal Amount
DebtSecuritiesAvailableForSalePrincipalAmount
1000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Weighted Average Yield
DebtSecuritiesAvailableForSaleWeightedAverageYield
0.08
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1165575 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1105935 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
165575 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
105935 usd
CY2024Q2 us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
19945 usd
CY2023Q2 us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
0 usd
us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
59640 usd
us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
0 usd
CY2024Q2 abl Number Of Entities In Which Equity Securities Without Readily Determinable Fair Value Are Held
NumberOfEntitiesInWhichEquitySecuritiesWithoutReadilyDeterminableFairValueAreHeld
2 entity
CY2024Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
1750000 usd
CY2023Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
1650000 usd
CY2024Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0 usd
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1507431 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
998945 usd
CY2024Q2 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
4008225 usd
CY2023Q4 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
2348998 usd
CY2024Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
4008225 usd
CY2023Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
2252891 usd
CY2024Q2 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
0 usd
CY2023Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
96107 usd
CY2024Q2 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
4008225 usd
CY2023Q4 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
2348998 usd
CY2024 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 segment
CY2024Q2 us-gaap Revenues
Revenues
29076102 usd
CY2023Q2 us-gaap Revenues
Revenues
11378765 usd
us-gaap Revenues
Revenues
50563286 usd
us-gaap Revenues
Revenues
21584974 usd
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
2743534 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
973400 usd
us-gaap Cost Of Revenue
CostOfRevenue
5464431 usd
us-gaap Cost Of Revenue
CostOfRevenue
1462950 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
26332568 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
10405365 usd
us-gaap Gross Profit
GrossProfit
45098855 usd
us-gaap Gross Profit
GrossProfit
20122024 usd
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2552801 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
683841 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4482745 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1412845 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14553344 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
577539 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25906843 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1274431 usd
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1750452 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1098 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3432506 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2141 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
195470 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
121601 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
142442 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21651 usd
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
667500 usd
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-279460 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4529187 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
584075 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
8199632 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
941458 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
639906 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
0 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1061332 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
7457 usd
CY2024Q2 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-1199463 usd
CY2023Q2 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-1445229 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-3912090 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-2398662 usd
CY2024Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-362482 usd
CY2023Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
672936 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
802484 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
798156 usd
CY2024Q2 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
856744 usd
CY2023Q2 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
0 usd
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
856744 usd
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
0 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1757710 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1184571 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2931223 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
528104 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-118234 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-26596 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-44960 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-487303 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
769983 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
6750145 usd
us-gaap Net Income Loss
NetIncomeLoss
-578762 usd
us-gaap Net Income Loss
NetIncomeLoss
14835648 usd
CY2024Q2 us-gaap Life Settlement Contracts Investment Method Carrying Amount
LifeSettlementContractsInvestmentMethodCarryingAmount
1140497 usd
CY2023Q4 us-gaap Life Settlement Contracts Investment Method Carrying Amount
LifeSettlementContractsInvestmentMethodCarryingAmount
1697178 usd
CY2024Q2 abl Sensitivity Analysis Of Fair Value Life Settlement Contracts Fair Value Impact Of2 Percent Positive Change In Discount Rate
SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate
194281144 usd
abl Sensitivity Analysis Of Fair Value Change In Life Settlement Contracts Fair Value Impact Of2 Percent Positive Change In Discount Rate
SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate
-13290269 usd
CY2024Q2 us-gaap Life Settlement Contracts Fair Value Method Carrying Amount
LifeSettlementContractsFairValueMethodCarryingAmount
207571413 usd
CY2024Q2 abl Sensitivity Analysis Of Fair Value Life Settlement Contracts Fair Value Impact Of2 Percent Adverse Change In Discount Rate
SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate
224830721 usd
abl Sensitivity Analysis Of Fair Value Change In Life Settlement Contracts Fair Value Impact Of2 Percent Adverse Change In Discount Rate
SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate
17259308 usd
CY2024Q2 abl Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets
FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets
-1287354 usd
abl Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets
FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets
-3990020 usd
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
55999 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
44049 usd
CY2024Q2 abl Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Equity Attributable To Noncontrolling Interest
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest
9616 usd
abl Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Equity Attributable To Noncontrolling Interest
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest
14130 usd
CY2024Q2 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-1199463 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-3912090 usd
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
68348556 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-3912090 usd
us-gaap Fair Value Option Credit Risk Gains Losses On Assets
FairValueOptionCreditRiskGainsLossesOnAssets
-59003 usd
abl Fair Value Option Credit Risk Gains Losses On Assets Included In Equity Attributable To Noncontrolling Interest
FairValueOptionCreditRiskGainsLossesOnAssetsIncludedInEquityAttributableToNoncontrollingInterest
-18927 usd
abl Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets
FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets
-3990020 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
290706 usd
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
99229992 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1165575 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1105935 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 abl Number Of Votes Per Common Share
NumberOfVotesPerCommonShare
1 vote
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75484567 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74436341 shares
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1048226 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62961688 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62961688 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63388823 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63242173 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
146650 shares
CY2024Q2 abl Sale Of Stock Over Allotment Option Term
SaleOfStockOverAllotmentOptionTerm
P30D
CY2023Q4 srt Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
15000000 usd
CY2023Q4 us-gaap Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
P18M
CY2024Q2 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
2974863 usd
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
146650 shares
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1283062 usd
CY2023Q4 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
8.82
CY2024Q1 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
316800 shares
CY2024Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
3664552 usd
CY2024Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
11.61
CY2024Q1 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
200916 shares
CY2024Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
2480383 usd
CY2024Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
12.35
CY2024Q1 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
114400 shares
CY2024Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1379457 usd
CY2024Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
12.06
CY2024Q2 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
173197 shares
CY2024Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
2081859 usd
CY2024Q2 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
12.02
CY2024Q2 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
96263 shares
CY2024Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1135824 usd
CY2024Q2 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
11.81
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1048226 shares
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
12025137 usd
CY2024Q2 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
11.61
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.2300
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0398
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M21D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
3.91
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
345263 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.91
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
345263 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.91
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2024Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
90716 usd
CY2023Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
13075 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
199532 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
25315 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1757710 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1184571 usd
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.730
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.150
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2931223 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
528104 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
1.270
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.035
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
359352 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2108034 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1893659 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297397 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
118058 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1946140 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1796727 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2243537 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1914785 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
128607 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
12471 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
250440 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
24942 usd
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
125476 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
7704 usd
us-gaap Variable Lease Cost
VariableLeaseCost
146245 usd
us-gaap Variable Lease Cost
VariableLeaseCost
8925 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
254083 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
20175 usd
us-gaap Lease Cost
LeaseCost
396685 usd
us-gaap Lease Cost
LeaseCost
33867 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
289498 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
24557 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
359352 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M3D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0967
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0354
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
23840 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
553953 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
570602 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
587694 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
605268 usd
CY2024Q2 abl Lessee Operating Lease Liability To Be Paid Due After Year Four
LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
623490 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2964847 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
721310 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2243537 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
769983 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6750145 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-578762 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
14835648 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63846170 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50507728 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63087878 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50438921 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
769983 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6750145 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-578762 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
14835648 usd
CY2024Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0 usd
CY2023Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0 usd
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-208631 usd
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
769983 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
6750145 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-787393 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
14835648 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63846170 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50507728 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63087878 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50438921 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67162820 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50507728 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63102210 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50438921 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.29
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001814287-24-000051-index-headers.html Edgar Link pending
0001814287-24-000051-index.html Edgar Link pending
0001814287-24-000051.txt Edgar Link pending
0001814287-24-000051-xbrl.zip Edgar Link pending
abl-20240630.htm Edgar Link pending
abl-20240630.xsd Edgar Link pending
abl-20240630_g1.jpg Edgar Link pending
exhibit311_certxablxfs0630.htm Edgar Link pending
exhibit312_certxablxfs0630.htm Edgar Link pending
exhibit321_certxablxfs0630.htm Edgar Link pending
exhibit322_certxablxfs0630.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R100.htm Edgar Link pending
R101.htm Edgar Link pending
abl-20240630_cal.xml Edgar Link unprocessable
abl-20240630_def.xml Edgar Link unprocessable
abl-20240630_lab.xml Edgar Link unprocessable
abl-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
abl-20240630_htm.xml Edgar Link completed
R102.htm Edgar Link pending
R103.htm Edgar Link pending
R104.htm Edgar Link pending
R105.htm Edgar Link pending
R106.htm Edgar Link pending
R107.htm Edgar Link pending
R108.htm Edgar Link pending
R109.htm Edgar Link pending
R11.htm Edgar Link pending
R110.htm Edgar Link pending
R111.htm Edgar Link pending
R112.htm Edgar Link pending
R113.htm Edgar Link pending
R114.htm Edgar Link pending
R115.htm Edgar Link pending
R116.htm Edgar Link pending
R117.htm Edgar Link pending
R118.htm Edgar Link pending
R119.htm Edgar Link pending
R12.htm Edgar Link pending
R120.htm Edgar Link pending
R121.htm Edgar Link pending
R122.htm Edgar Link pending
R123.htm Edgar Link pending
R124.htm Edgar Link pending
R125.htm Edgar Link pending
R126.htm Edgar Link pending
R127.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
R99.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending